H3 Opens Labs In Cambridge, Mass. | Chemical & Engineering News
Volume 89 Issue 50 | p. 17 | Concentrates
Issue Date: December 12, 2011

H3 Opens Labs In Cambridge, Mass.

Department: Business
Keywords: drug discovery, oncology, small molecules
[+]Enlarge
Eisai CEO Haruo Naito (left) and H3 CEO Markus Warmuth tour H3’s new labs.
Credit: H3 Biomedicine
Pictured: Haruo Naito, President & CEO of Eisai Co. Ltd. of Japan (left), and Markus Warmuth, M.D., President & CEO of H3 Biomedicine Inc. at H3 laboratories in Cambridge, MA.
 
Eisai CEO Haruo Naito (left) and H3 CEO Markus Warmuth tour H3’s new labs.
Credit: H3 Biomedicine

H3 Biomedicine has opened new headquarters and 24,000 sq ft of lab space in Cambridge, Mass. Launched in January, the small-molecule oncology drug firm plans to increase its staff to 70 people over the next year. H3’s scientific founders are Stuart Schreiber and Todd Golub of the Broad Institute of Harvard University and MIT. H3 is backed by the Japanese drug company Eisai, which has pledged up to $200 million in research funding to H3.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment